… -kinase inhibitor erlotinib has … the phase 3, placebo-controlled Sequential Tarceva in
Unresectable NSCLC (SATURN; BO18192) study to assess use of erlotinib as maintenance therapy …

… Based on the rationales, we hypothesized that low-dose erlotinib would be safe and …
multicenter phase 2 clinical trial to investigate the efficacy and safety of low-dose erlotinib in …

… A multicenter randomized phase II trial to evaluate two treatment strategies in the first-line
management of advanced non–small-cell lung cancer (NSCLC) patients with a performance …

… erlotinib were rash, fatigue, and hypomagnesemia. The recommended phase II dose identified
was cetuximab 500 mg/m 2 every 2 … results of a trial combining erlotinib and cetuximab in …

… randomized studies that investigated erlotinib or gefitinib in … a phase II study of single-agent
erlotinib as first-line therapy … study to identify patients who benefited most from treatment. …

… NSCLC were treated with erlotinib with or without sorafenib in this multicenter phase II trial.
… to patients with relapsed NSCLC in a multicenter phase II trial. Fifty-nine percent of patients …

… 2 during erlotinib treatment and 22 after stopping erlotinib with a median time to recurrence
of 12 months after stopping erlotinib. … -treated with erlotinib with 10 pts remaining on erlotinib, …

… the results from phase II trials of erlotinib in other disease sites, [18] and from other EGFR-targeted
therapies, [17,19] clinical outcome of erlotinib in the current study correlated with the …

… contribute to the benefit observed with sequential erlotinib in this study. Indeed, two patients
with EGFR mutations obtained a substantial benefit with sequential erlotinib (PFS, 56 to 82+ …

… bevacizumab and erlotinib may be synergistic in this regard. This study reports the results of
a multi-institution phase II trial of bevacizumab and erlotinib combination therapy for patients …